查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2089116

肥胖症治療市場：2026-2032年全球市場預測（依治療類型、給藥途徑、病患年齡層、性別、肥胖類型、銷售管道和最終用戶分類）

Obesity Treatment Market by Treatment Type, Route of Administration, Patient Age Group, Gender, Obesity Type, Distribution Channel, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，肥胖症治療市場將成長至 613.8 億美元，複合年成長率為 15.64%。

主要市場統計數據
基準年 2025 221.9億美元
預計年份：2026年 254.6億美元
預測年份 2032 613.8億美元
複合年成長率 (%) 15.64%

肥胖治療市場簡介

肥胖症的治療正從暫時性的減重管理轉向基於實證醫學的慢性病管理。世界衛生組織（世衛組織）的數據顯示，到2022年，全球將有超過10億人患有肥胖症，其中包括8.79億成年人和1.59億兒童及青少年，使其成為全球最嚴重的健康負擔之一。

肥胖症護理的變革性變化

隨著GLP-1受體促效劑和雙重腸促胰島素療法重新定義了臨床上對持續減重的預期，肥胖症治療格局正在經歷結構性變化。突破性的臨床試驗結果，包括司Semaglutide可降低某些已確診心血管疾病的肥胖患者的心血管風險的證據，已將肥胖症治療從單純的美容性減重提升為基於風險的醫療干預。

人工智慧（AI）的累積影響

人工智慧 (AI) 透過改善患者識別、風險分層、治療方案選擇和藥物依從性支持，正在加速肥胖症的治療。 AI 驅動的分析可以分析電子健康記錄，識別出可能受益於藥物治療、強化生活方式介入或減重手術的肥胖相關併發症患者。

關鍵區域洞察

北美地區由於肥胖症高發生率、擁有強大的專家網路以及新型抗肥胖藥物的快速普及，仍然是肥胖症治療的重要區域。根據美國疾病管制與預防中心（CDC）的數據，2021年8月至2023年8月，美國成人肥胖症盛行率高達40.3%，導致對藥物、手術、行為介入和數位化介入的需求持續旺盛。同時，加拿大在將肥胖症納入以指南為基礎的醫療保健體系中，並使其成為一種慢性疾病方面取得了進展。歐洲以全民健保、醫療技術評估和成本效益審查為特徵，德國、法國、義大利、西班牙和英國等國在預防重點與獲得先進藥物療法和減肥手術服務之間取得了平衡。

主要群體分析

七國集團（G7）擁有最集中的先進肥胖症治療基礎設施，包括臨床研究能力、保險報銷機制、監管成熟度和專業的肥胖症護理。雖然歐盟透過歐洲藥品管理局（EMA）協調藥品監管，但醫療保健的可近性和成本控制取決於各國的醫療保健體系，因此，證據產生、療效比較和衛生經濟價值對於實施至關重要。

主要國家的概況

由於肥胖症盛行率高、藥物使用積極、雇主重視、專業基礎設施完善以及保險覆蓋範圍的積極討論，美國是肥胖症治療領域商業性最活躍的市場。加拿大則透過臨床指引和多學科服務，著重關注慢性疾病，推進肥胖症的治療。同時，墨西哥和巴西面臨肥胖和糖尿病帶來的沉重負擔，凸顯了對藥物治療、手術治療、營養療法和生活方式乾預等解決方案的需求。

為行業領導者提供的實用建議

行業領導者應優先考慮以證據為基礎的定位，將減重與可衡量的代謝、心血管、功能和生活品質 (QOL) 結果聯繫起來。商業策略應將肥胖症定位為一種慢性、復發性疾病，需要維持治療、藥物順從性支持、分階段強化個人化治療、長期病患監測。

調查方法

本執行摘要是基於公開的、有數據支持的二手研究資訊來源編寫而成，這些資料包括世界衛生組織、美國疾病控制與預防中心、各國衛生機構、監管機構的官方出版刊物、同行評審的臨床試驗、臨床指南以及公共醫療衛生系統的相關數據。研究從多個角度檢驗了相關觀點，包括流行病學、治療可近性、監管趨勢、保險報銷趨勢、臨床結果以及當地醫療衛生基礎設施。

結論

肥胖症治療正進入一個新階段，其特徵是慢性病管理、先進的藥物治療、多學科協作以及數據驅動的患者參與。肥胖症的全球規模，以及將治療與更廣泛的健康結果聯繫起來的臨床證據，正在提升肥胖症治療在整個醫療保健系統中的戰略重要性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：肥胖症治療市場：依治療類型分類

  • 藥物治療
    • 食慾抑制劑
    • 脂肪酶抑制劑
    • GLP-1受體促效劑
    • 聯合治療
  • 手術治療
    • 胃繞道手術
    • 袖狀切除術
    • 可調式胃束帶手術
    • 膽胰分流術合併十二指腸轉位術
  • 使用醫療設備進行治療
    • 胃內球囊
    • 內視鏡袖狀胃切除術
    • 電刺激系統

第8章：肥胖症治療市場：依給藥途徑分類

  • 口服
  • 注射藥物
  • 經皮給藥

第9章：肥胖症治療市場：依患者年齡層別分類

  • 成人
  • 老年人
  • 兒童

第10章 肥胖症治療市場：依性別分類

  • 男性
  • 女士

第11章 肥胖症治療市場：依肥胖症類型分類

  • 一級（BMI 30-35）
  • 類別II（BMI 35-40）
  • 三級（重度/病態肥胖，BMI 40或更高）

第12章 肥胖症治療市場：依通路分類

  • 離線
  • 線上

第13章 肥胖症治療市場：依最終使用者分類

  • 醫院和診所
  • 專科診所
  • 減重與健康中心

第14章 肥胖症治療市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第15章 肥胖症治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 肥胖症治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第18章：公司簡介

  • Novo Nordisk A/S
  • Eli Lilly and Company
  • WW International, Inc.
  • Amgen Inc.
  • Noom, Inc.
  • AstraZeneca PLC
  • Herbalife Ltd.
  • Hims & Hers Health, Inc.
  • Rhythm Pharmaceuticals, Inc.
  • Zealand Pharma A/S
  • Omada Health Inc.
  • Boston Scientific Corporation
  • IEH Biopharma LLC
  • Medifast, Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Pfizer, Inc.
  • Viking Therapeutics, Inc.
  • Currax Pharmaceuticals LLC
  • ReShape Lifesciences, Inc.
  • AbbVie Inc.
  • Atkins Nutritionals, Inc.
  • BTL Aesthetics
  • CH Boehringer Sohn AG & Ko. KG
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline plc.
  • Johnson & Johnson Services, Inc.
  • Kellogg Company
  • Medtronic PLC
  • Merck & Co.
  • NutriSystem, Inc.
  • Olympus Corporation
Product Code: MRR-EC2E133E32E2

The Obesity Treatment Market is projected to grow by USD 61.38 billion at a CAGR of 15.64% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 22.19 billion
Estimated Year [2026] USD 25.46 billion
Forecast Year [2032] USD 61.38 billion
CAGR (%) 15.64%

Obesity Treatment Market Introduction

Obesity treatment has moved from episodic weight-loss management to evidence-based chronic disease care. The World Health Organization reports that more than 1 billion people were living with obesity in 2022, including 879 million adults and 159 million children and adolescents, making the condition one of the most significant global health burdens.

Demand is being driven by rising cardiometabolic disease, broader clinical acceptance of anti-obesity medications, expanding bariatric and endoscopic options, and payer interest in reducing obesity-linked costs from type 2 diabetes, cardiovascular disease, sleep apnea, osteoarthritis, and certain cancers. Clinical guidelines increasingly position obesity management as long-term care that combines lifestyle intervention, pharmacotherapy, surgical evaluation, behavioral support, and continuous monitoring.

Transformative Shifts in Obesity Care

The obesity treatment landscape is undergoing a structural shift as GLP-1 receptor agonists and dual incretin therapies redefine clinical expectations for durable weight reduction. Landmark trial results, including cardiovascular risk reduction evidence for semaglutide in selected patients with obesity and established cardiovascular disease, have elevated obesity treatment from cosmetic weight loss to risk-based medical intervention.

At the same time, care delivery is becoming multidisciplinary. Nutrition therapy, behavioral health, remote monitoring, pharmacotherapy, bariatric surgery, and maintenance programs are increasingly integrated to improve adherence, minimize weight regain, and support long-term metabolic outcomes. Regulatory agencies and clinical societies are also emphasizing safety surveillance, patient selection, and continuity of care as demand for evidence-backed obesity treatment accelerates.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is accelerating obesity treatment by improving patient identification, risk stratification, treatment matching, and adherence support. AI-enabled analytics can mine electronic health records to identify patients with obesity-related complications who may benefit from pharmacotherapy, intensive lifestyle intervention, or bariatric evaluation.

The cumulative impact is strongest where AI supports clinical workflow rather than replacing clinician judgment. Predictive models, connected scales, digital coaching, and automated prior authorization tools can reduce friction in care pathways, while safeguards for bias, privacy, interoperability, and clinical validation remain essential. AI can also support real-world evidence generation by tracking persistence, adverse events, weight trajectories, and cardiometabolic outcomes across diverse patient populations.

Key Regional Insights

North America remains a high-value obesity treatment region due to elevated disease prevalence, strong specialist networks, and fast uptake of novel anti-obesity medications. CDC data show U.S. adult obesity prevalence at 40.3% for August 2021 to August 2023, sustaining demand for medical, surgical, behavioral, and digital interventions, while Canada continues to advance obesity as a chronic disease within guideline-led care. Europe is shaped by universal health systems, health technology assessment, and cost-effectiveness scrutiny, with Germany, France, Italy, Spain, and the United Kingdom balancing prevention priorities with access to advanced pharmacotherapy and bariatric services.

Asia-Pacific is expanding as urbanization, dietary change, and sedentary lifestyles increase obesity and diabetes risk, especially across China, India, Australia, Japan, and South Korea. Latin America, led by Brazil and Mexico, faces high obesity and diabetes burdens but uneven reimbursement and fragmented access to specialist care. The Middle East, particularly GCC markets, is prioritizing obesity because of high diabetes prevalence and national chronic disease strategies, while Africa is managing a dual burden of undernutrition and rising obesity in urban populations, increasing the need for scalable prevention, primary care screening, and affordable treatment pathways.

Key Group Insights

The G7 has the strongest concentration of advanced obesity treatment infrastructure, including clinical research capacity, reimbursement pathways, regulatory maturity, and specialist obesity care. The European Union supports harmonized drug regulation through the European Medicines Agency, while national health systems determine access and cost controls, making evidence generation, comparative effectiveness, and health-economic value critical for adoption.

BRICS countries combine very large patient pools with uneven access to specialist care, creating opportunities for scalable, lower-cost care models, local manufacturing, and primary care-led obesity management. ASEAN markets are influenced by rapid urbanization, nutrition transition, and growing diabetes prevalence, while GCC countries are investing in chronic disease management, digital health infrastructure, and premium healthcare services. NATO is not a health bloc, but its member countries increasingly view metabolic health as relevant to workforce readiness, healthcare system resilience, and long-term productivity.

Key Country Insights

The United States is the most commercially dynamic obesity treatment market because of high prevalence, strong drug adoption, employer interest, specialist capacity, and active debate on insurance coverage. Canada is advancing chronic disease-oriented obesity care through clinical guidelines and multidisciplinary services, while Mexico and Brazil face substantial obesity and diabetes burdens that support demand for accessible pharmacologic, surgical, nutritional, and lifestyle-based solutions.

In Europe, the United Kingdom, Germany, France, Italy, and Spain are expanding obesity services under budget-sensitive public systems, with reimbursement tied to evidence, clinical prioritization, and health technology assessment. Russia presents a large population base with variable access to advanced therapies and specialist obesity management. China and India have enormous addressable populations and rising metabolic disease risk linked to urbanization and lifestyle change, while Japan, South Korea, and Australia show strong demand for clinically validated, guideline-aligned care models that integrate pharmacotherapy, digital support, and long-term monitoring.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize evidence-based positioning that connects weight reduction with measurable metabolic, cardiovascular, functional, and quality-of-life outcomes. Commercial strategies should align with obesity as a chronic, relapsing disease requiring maintenance therapy, adherence support, individualized escalation, and long-term patient monitoring.

Organizations should expand partnerships with payers, employers, health systems, primary care networks, and digital health platforms to improve access and persistence. Investment in real-world evidence, safety monitoring, supply reliability, clinician education, culturally tailored care, and affordability will be critical as demand outpaces traditional obesity care capacity. Leaders should also prepare for stricter scrutiny around patient selection, long-term safety, discontinuation outcomes, and equitable access.

Research Methodology

This executive summary is developed through secondary research using publicly available, data-backed sources including WHO, CDC, national health agencies, regulatory bodies, peer-reviewed clinical trials, clinical guidelines, and official health system publications. Insights are triangulated across epidemiology, treatment adoption, regulatory activity, reimbursement trends, clinical outcomes, and regional healthcare infrastructure.

The methodology emphasizes verified facts, market-relevant interpretation, and cross-regional comparison. No unsupported market-sizing claims are used; conclusions are framed around documented disease burden, approved therapies, clinical evidence, real-world care dynamics, and observable healthcare system trends. Regional, group, and country insights are synthesized narratively to maintain clarity, and decision-useful context.

Conclusion

Obesity treatment is entering a new phase defined by chronic disease management, advanced pharmacotherapy, multidisciplinary care, and data-enabled patient engagement. The scale of global obesity, combined with clinical evidence linking treatment to broader health outcomes, is expanding the strategic importance of obesity care across healthcare systems.

Organizations that pair scientific credibility with access strategies, digital support, supply resilience, and long-term outcome measurement will be best positioned to capture growth while improving population health. Sustainable success will depend on demonstrating durable outcomes, supporting equitable access, and integrating obesity treatment into routine cardiometabolic care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Obesity Treatment Market, by Treatment Type

  • 7.1. Pharmacological Treatments
    • 7.1.1. Appetite Suppressants
    • 7.1.2. Lipase Inhibitors
    • 7.1.3. GLP-1 Receptor Agonists
    • 7.1.4. Combination Therapies
  • 7.2. Surgical Treatments
    • 7.2.1. Gastric Bypass
    • 7.2.2. Sleeve Gastrectomy
    • 7.2.3. Adjustable Gastric banding
    • 7.2.4. Biliopancreatic Diversion with Duodenal switch
  • 7.3. Device-Based Treatments
    • 7.3.1. Intragastric Balloons
    • 7.3.2. Endoscopic Sleeve Gastroplasty
    • 7.3.3. Electrical Stimulation Systems

8. Obesity Treatment Market, by Route of Administration

  • 8.1. Oral
  • 8.2. Injectable
  • 8.3. Transdermal

9. Obesity Treatment Market, by Patient Age Group

  • 9.1. Adults
  • 9.2. Elderly
  • 9.3. Pediatric

10. Obesity Treatment Market, by Gender

  • 10.1. Male
  • 10.2. Female

11. Obesity Treatment Market, by Obesity Type

  • 11.1. Class I (BMI 30-35)
  • 11.2. Class II (BMI 35-40)
  • 11.3. Class III (Severe/Morbid obesity, BMI >=40)

12. Obesity Treatment Market, by Distribution Channel

  • 12.1. Offline
  • 12.2. Online

13. Obesity Treatment Market, by End-User

  • 13.1. Hospitals & Clinics
  • 13.2. Specialty Clinics
  • 13.3. Weight Loss & Wellness Centers

14. Obesity Treatment Market, by Region

  • 14.1. Asia-Pacific
  • 14.2. North America
  • 14.3. Latin America
  • 14.4. Europe
  • 14.5. Middle East
  • 14.6. Africa

15. Obesity Treatment Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Obesity Treatment Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025

18. Company Profiles

  • 18.1. Novo Nordisk A/S
  • 18.2. Eli Lilly and Company
  • 18.3. WW International, Inc.
  • 18.4. Amgen Inc.
  • 18.5. Noom, Inc.
  • 18.6. AstraZeneca PLC
  • 18.7. Herbalife Ltd.
  • 18.8. Hims & Hers Health, Inc.
  • 18.9. Rhythm Pharmaceuticals, Inc.
  • 18.10. Zealand Pharma A/S
  • 18.11. Omada Health Inc.
  • 18.12. Boston Scientific Corporation
  • 18.13. IEH Biopharma LLC
  • 18.14. Medifast, Inc.
  • 18.15. Sanofi SA
  • 18.16. Takeda Pharmaceutical Company Limited
  • 18.17. Pfizer, Inc.
  • 18.18. Viking Therapeutics, Inc.
  • 18.19. Currax Pharmaceuticals LLC
  • 18.20. ReShape Lifesciences, Inc.
  • 18.21. AbbVie Inc.
  • 18.22. Atkins Nutritionals, Inc.
  • 18.23. BTL Aesthetics
  • 18.24. C.H. Boehringer Sohn AG & Ko. KG
  • 18.25. F. Hoffmann-La Roche Ltd
  • 18.26. GlaxoSmithKline plc.
  • 18.27. Johnson & Johnson Services, Inc.
  • 18.28. Kellogg Company
  • 18.29. Medtronic PLC
  • 18.30. Merck & Co.
  • 18.31. NutriSystem, Inc.
  • 18.32. Olympus Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL OBESITY TREATMENT MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL OBESITY TREATMENT MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL OBESITY TREATMENT MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL OBESITY TREATMENT MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL OBESITY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL OBESITY TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL OBESITY TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL OBESITY TREATMENT MARKET SIZE, BY GENDER, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL OBESITY TREATMENT MARKET SIZE, BY GENDER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL OBESITY TREATMENT MARKET SIZE, BY OBESITY TYPE, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL OBESITY TREATMENT MARKET SIZE, BY OBESITY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL OBESITY TREATMENT MARKET SIZE, BY END-USER, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL OBESITY TREATMENT MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL OBESITY TREATMENT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL OBESITY TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL OBESITY TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL OBESITY TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 27. GLOBAL OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL OBESITY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PHARMACOLOGICAL TREATMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PHARMACOLOGICAL TREATMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PHARMACOLOGICAL TREATMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL APPETITE SUPPRESSANTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL APPETITE SUPPRESSANTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL APPETITE SUPPRESSANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL LIPASE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL LIPASE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL LIPASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL GLP-1 RECEPTOR AGONISTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL GLP-1 RECEPTOR AGONISTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL GLP-1 RECEPTOR AGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL COMBINATION THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL COMBINATION THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL COMBINATION THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL SURGICAL TREATMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL SURGICAL TREATMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL SURGICAL TREATMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL GASTRIC BYPASS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL GASTRIC BYPASS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL GASTRIC BYPASS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL SLEEVE GASTRECTOMY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL SLEEVE GASTRECTOMY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL SLEEVE GASTRECTOMY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ADJUSTABLE GASTRIC BANDING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ADJUSTABLE GASTRIC BANDING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ADJUSTABLE GASTRIC BANDING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BILIOPANCREATIC DIVERSION WITH DUODENAL SWITCH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BILIOPANCREATIC DIVERSION WITH DUODENAL SWITCH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BILIOPANCREATIC DIVERSION WITH DUODENAL SWITCH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DEVICE-BASED TREATMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DEVICE-BASED TREATMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DEVICE-BASED TREATMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL INTRAGASTRIC BALLOONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL INTRAGASTRIC BALLOONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL INTRAGASTRIC BALLOONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ENDOSCOPIC SLEEVE GASTROPLASTY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ENDOSCOPIC SLEEVE GASTROPLASTY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ENDOSCOPIC SLEEVE GASTROPLASTY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ELECTRICAL STIMULATION SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ELECTRICAL STIMULATION SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ELECTRICAL STIMULATION SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL TRANSDERMAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL TRANSDERMAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL TRANSDERMAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ADULTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ADULTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ADULTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ELDERLY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ELDERLY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ELDERLY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL OBESITY TREATMENT MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL MALE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL MALE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL MALE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL FEMALE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL FEMALE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL FEMALE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL OBESITY TREATMENT MARKET SIZE, BY OBESITY TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CLASS I (BMI 30-35) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CLASS I (BMI 30-35) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CLASS I (BMI 30-35) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CLASS II (BMI 35-40) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CLASS II (BMI 35-40) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CLASS II (BMI 35-40) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CLASS III (SEVERE/MORBID OBESITY, BMI >=40) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CLASS III (SEVERE/MORBID OBESITY, BMI >=40) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CLASS III (SEVERE/MORBID OBESITY, BMI >=40) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ONLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL WEIGHT LOSS & WELLNESS CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL WEIGHT LOSS & WELLNESS CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL WEIGHT LOSS & WELLNESS CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL OBESITY TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY DEVICE-BASED TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY OBESITY TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY DEVICE-BASED TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY OBESITY TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY DEVICE-BASED TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY OBESITY TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE OBESITY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE OBESITY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE OBESITY TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE OBESITY TREATMENT MARKET SIZE, BY DEVICE-BASED TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE OBESITY TREATMENT MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE OBESITY TREATMENT MARKET SIZE, BY OBESITY TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY DEVICE-BASED TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY OBESITY TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA OBESITY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA OBESITY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA OBESITY TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA OBESITY TREATMENT MARKET SIZE, BY DEVICE-BASED TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA OBESITY TREATMENT MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA OBESITY TREATMENT MARKET SIZE, BY OBESITY TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL OBESITY TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN OBESITY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN OBESITY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN OBESITY TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN OBESITY TREATMENT MARKET SIZE, BY DEVICE-BASED TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN OBESITY TREATMENT MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN OBESITY TREATMENT MARKET SIZE, BY OBESITY TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 178. GCC OBESITY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 179. GCC OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. GCC OBESITY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 181. GCC OBESITY TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 182. GCC OBESITY TREATMENT MARKET SIZE, BY DEVICE-BASED TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 183. GCC OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 184. GCC OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 185. GCC OBESITY TREATMENT MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 186. GCC OBESITY TREATMENT MARKET SIZE, BY OBESITY TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. GCC OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 188. GCC OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION OBESITY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION OBESITY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION OBESITY TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION OBESITY TREATMENT MARKET SIZE, BY DEVICE-BASED TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION OBESITY TREATMENT MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION OBESITY TREATMENT MARKET SIZE, BY OBESITY TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS OBESITY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS OBESITY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS OBESITY TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS OBESITY TREATMENT MARKET SIZE, BY DEVICE-BASED TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS OBESITY TREATMENT MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS OBESITY TREATMENT MARKET SIZE, BY OBESITY TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 211. G7 OBESITY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 212. G7 OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. G7 OBESITY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 214. G7 OBESITY TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 215. G7 OBESITY TREATMENT MARKET SIZE, BY DEVICE-BASED TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 216. G7 OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 217. G7 OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 218. G7 OBESITY TREATMENT MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 219. G7 OBESITY TREATMENT MARKET SIZE, BY OBESITY TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. G7 OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 221. G7 OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 222. NATO OBESITY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 223. NATO OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. NATO OBESITY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 225. NATO OBESITY TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 226. NATO OBESITY TREATMENT MARKET SIZE, BY DEVICE-BASED TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 227. NATO OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 228. NATO OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 229. NATO OBESITY TREATMENT MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 230. NATO OBESITY TREATMENT MARKET SIZE, BY OBESITY TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. NATO OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 232. NATO OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 233. GLOBAL OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES OBESITY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES OBESITY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES OBESITY TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES OBESITY TREATMENT MARKET SIZE, BY DEVICE-BASED TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED STATES OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED STATES OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED STATES OBESITY TREATMENT MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED STATES OBESITY TREATMENT MARKET SIZE, BY OBESITY TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED STATES OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 245. CANADA OBESITY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 246. CANADA OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. CANADA OBESITY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 248. CANADA OBESITY TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 249. CANADA OBESITY TREATMENT MARKET SIZE, BY DEVICE-BASED TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 250. CANADA OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 251. CANADA OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 252. CANADA OBESITY TREATMENT MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 253. CANADA OBESITY TREATMENT MARKET SIZE, BY OBESITY TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. CANADA OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 255. CANADA OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 256. MEXICO OBESITY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 257. MEXICO OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 258. MEXICO OBESITY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 259. MEXICO OBESITY TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 260. MEXICO OBESITY TREATMENT MARKET SIZE, BY DEVICE-BASED TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 261. MEXICO OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 262. MEXICO OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 263. MEXICO OBESITY TREATMENT MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 264. MEXICO OBESITY TREATMENT MARKET SIZE, BY OBESITY TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. MEXICO OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 266. MEXICO OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 267. BRAZIL OBESITY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 268. BRAZIL OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 269. BRAZIL OBESITY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 270. BRAZIL OBESITY TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 271. BRAZIL OBESITY TREATMENT MARKET SIZE, BY DEVICE-BASED TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 272. BRAZIL OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 273. BRAZIL OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 274. BRAZIL OBESITY TREATMENT MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 275. BRAZIL OBESITY TREATMENT MARKET SIZE, BY OBESITY TYPE, 2018-2032 (USD MILLION)
  • TABLE 276. BRAZIL OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 277. BRAZIL OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 278. UNITED KINGDOM OBESITY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 279. UNITED KINGDOM OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 280. UNITED KINGDOM OBESITY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 281. UNITED KINGDOM OBESITY TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 282. UNITED KINGDOM OBESITY TREATMENT MARKET SIZE, BY DEVICE-BASED TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 283. UNITED KINGDOM OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 284. UNITED KINGDOM OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 285. UNITED KINGDOM OBESITY TREATMENT MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 286. UNITED KINGDOM OBESITY TREATMENT MARKET SIZE, BY OBESITY TYPE, 2018-2032 (USD MILLION)
  • TABLE 287. UNITED KINGDOM OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 288. UNITED KINGDOM OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 289. GERMANY OBESITY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 290. GERMANY OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 291. GERMANY OBESITY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 292. GERMANY OBESITY TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 293. GERMANY OBESITY TREATMENT MARKET SIZE, BY DEVICE-BASED TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 294. GERMANY OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 295. GERMANY OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 296. GERMANY OBESITY TREATMENT MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 297. GERMANY OBESITY TREATMENT MARKET SIZE, BY OBESITY TYPE, 2018-2032 (USD MILLION)
  • TABLE 298. GERMANY OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 299. GERMANY OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 300. FRANCE OBESITY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 301. FRANCE OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 302. FRANCE OBESITY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 303. FRANCE OBESITY TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 304. FRANCE OBESITY TREATMENT MARKET SIZE, BY DEVICE-BASED TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 305. FRANCE OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 306. FRANCE OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 307. FRANCE OBESITY TREATMENT MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 308. FRANCE OBESITY TREATMENT MARKET SIZE, BY OBESITY TYPE, 2018-2032 (USD MILLION)
  • TABLE 309. FRANCE OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 310. FRANCE OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 311. RUSSIA OBESITY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 312. RUSSIA OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 313. RUSSIA OBESITY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 314. RUSSIA OBESITY TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 315. RUSSIA OBESITY TREATMENT MARKET SIZE, BY DEVICE-BASED TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 316. RUSSIA OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 317. RUSSIA OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 318. RUSSIA OBESITY TREATMENT MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 319. RUSSIA OBESITY TREATMENT MARKET SIZE, BY OBESITY TYPE, 2018-2032 (USD MILLION)
  • TABLE 320. RUSSIA OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 321. RUSSIA OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 322. ITALY OBESITY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 323. ITALY OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 324. ITALY OBESITY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 325. ITALY OBESITY TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 326. ITALY OBESITY TREATMENT MARKET SIZE, BY DEVICE-BASED TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 327. ITALY OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 328. ITALY OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 329. ITALY OBESITY TREATMENT MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 330. ITALY OBESITY TREATMENT MARKET SIZE, BY OBESITY TYPE, 2018-2032 (USD MILLION)
  • TABLE 331. ITALY OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 332. ITALY OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 333. SPAIN OBESITY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 334. SPAIN OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 335. SPAIN OBESITY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 336. SPAIN OBESITY TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 337. SPAIN OBESITY TREATMENT MARKET SIZE, BY DEVICE-BASED TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 338. SPAIN OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 339. SPAIN OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 340. SPAIN OBESITY TREATMENT MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 341. SPAIN OBESITY TREATMENT MARKET SIZE, BY OBESITY TYPE, 2018-2032 (USD MILLION)
  • TABLE 342. SPAIN OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 343. SPAIN OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 344. CHINA OBESITY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 345. CHINA OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 346. CHINA OBESITY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 347. CHINA OBESITY TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 348. CHINA OBESITY TREATMENT MARKET SIZE, BY DEVICE-BASED TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 349. CHINA OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 350. CHINA OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 351. CHINA OBESITY TREATMENT MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 352. CHINA OBESITY TREATMENT MARKET SIZE, BY OBESITY TYPE, 2018-2032 (USD MILLION)
  • TABLE 353. CHINA OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 354. CHINA OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 355. INDIA OBESITY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 356. INDIA OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 357. INDIA OBESITY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 358. INDIA OBESITY TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032